Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 1998

View Archived Issues

IL-1 blockers CK-119 and CK-122 inhibit corneal fibroblast-like cell proliferation

Pivotal clinical trial data for rituximab published

Genzyme General and Knoll reach copromotion agreement for Thyrogen

Genset enters into Chlamydia vaccine license agreement with AHP

MDI-P demonstrates potent anti-HIV activity in preclinical studies

Scientists solve 3D structure of enzyme that confers bacterial resistance to gentamicin

Hoechst Marion Roussel and 3M file NDA for QVAR

MorphoSys and LeukoSite enter collaboration agreement

Novel antitumor antibiotics isolated from Streptomyces by Japanese researchers

P&G reports alpha2-adrenoceptor agonists for treating nasal congestion

T Cell Sciences-Virus Research Institute merger completed; Avant up and running

Ergo Science submits amendment to Ergoset NDA

Isis Pharmaceuticals: Q2 1998 highlights

Pharmacia & Upjohn: Q2 1998 highlights

NDA application submitted for Orphan Medical's Busulfex injection

Bayer reports new agents for treating cardiovascular disease

Wakunaga discloses new antibacterial agents in early development

New cephalosporin derivatives active against MRSA

Contrast agent from Nycomed Imaging proves useful for several applications

AR-C69931MX; a novel P2T antagonist with platelet aggregation-inhibitory activity

ETA antagonism with LU-135252 may provide novel antiischemic therapy

Preclinical and clinical data reported for orbofiban, a potent antiplatelet agent

News from the ACS: Roche synthesizes selective 5-HT2C antagonists

Profile of VPA-985, Wyeth-Ayerst's aquaretic agent in clinical trials

Another beta3-adrenergic agent added to the BMS pipeline

Proteus applies prion antibody technology to develop a test for CJD

Phase II study establishes feasibility, safety of pioneering restenosis treatment

News from the ACS: Lilly investigates antioxidants for treating neuronal injury

BioCryst identifies development candidate in complement inhibitor program

WAY-140288: a follow-up V2 antagonist and aquaretic agent from Wyeth-Ayerst

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...